The MD-360 Equity Report—A History in the Affairs of MannKind’s Revolutionary Diabetes Treatment

Editor NotesWe are long on MNKD as of the publication of this article back in June 2014. We sold out our stock a while back, but continue to be confident in this thesis. In 2013, we wrote our first PRO article on Mannkind through Seeking Alpha. The stock had appreciated more than 40 percent since our publication. We strongly believe that the company is still highly undervalued, based on conservative valuation models and the upcoming catalysts. The aforesaid firm is one of the most powerful biopharmaceuticals among hundreds we studied. Last but not least, this is an ongoing work to be updated as time permits.

The full article is available at this link.